July 17, 2026
The federal government asked the U.S. Court of Federal Claims on Friday to dismiss much of a patent suit against it by Arbutus Biopharma tied to Moderna's COVID-19 vaccine, saying the court couldn't hear the bulk of the case because Arbutus and Moderna reached a multibillion-dollar consent judgment that is subject to appeal.
July 16, 2026
Drugmakers like Novartis, former federal judges, a startup group and others have urged the Federal Circuit to reject calls to shift liability in a COVID-19 vaccine patent suit against Moderna to the federal government, saying that doing so would undermine patent rights.
July 14, 2026
Conservative advocacy organization Eagle Forum Education & Legal Defense Fund on Tuesday urged the Federal Circuit to reject a proposal to shift a multibillion-dollar patent infringement case over the COVID-19 vaccine that is targeting Moderna to the federal government, saying doing so would reduce the crucial economic incentives that power innovation in the pharmaceutical industry.
June 22, 2026
The U.S. Department of Justice has told the Federal Circuit that multibillion-dollar patent infringement litigation should be directed at the government, instead of Moderna, for the drugmaker's development and supply of COVID vaccines during the pandemic.
June 08, 2026
The American Intellectual Property Law Association, National Association of Manufacturers and others urged the Federal Circuit to undo a lower court's ruling that Moderna, and not the government, must face a multibillion-dollar patent infringement suit over its COVID-19 vaccine.
June 01, 2026
Moderna has urged the Federal Circuit to rule that Arbutus Biopharma must pursue its patent infringement claims over Moderna's COVID-19 vaccine against the U.S. government, saying a lower court ruling that Moderna must face the multibillion-dollar suit was "deeply flawed."